BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 26, 2020
View Archived Issues
Atherosclerosis, AD meet at the myelin
Read More
p53 loss leads to immune evasion
Read More
Karus Therapeutics initiates phase II study of KA-2507 in biliary tract cancer
Read More
Enrollment open in phase II study of MSTT-1041A or UTTR-1147A in COVID-19 pneumonia
Read More
Clinical data for novel non-D2-receptor-binding compound in patients with schizophrenia
Read More
DNA-encoded immunotherapies show efficacy in models of N. gonorrhoeae infection
Read More
First-in-human characterization of RPT-193
Read More
IRAK-2 is a therapeutic target in atopic dermatitis and psoriasis
Read More
AiCuris discovers HBV caspid assembly inhibitors
Read More
New SSAO inhibitors identified at Boehringer Ingelheim
Read More
Esteve patents voltage-dependent calcium channel subunit alpha2/delta-1 ligands
Read More
Merck & Co. identifies new LRRK2 inhibitors
Read More
New TYK2 inhibitors disclosed by Bristol-Myers Squibb
Read More
Germline ApoE variants affect melanoma trajectory
Read More
PEG10 found behind pathogenic mechanisms of mycosis fungoides
Read More
Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint
Read More
Chi-Med and BeiGene to study surufatinib and fruquintinib with tislelizumab for solid tumors
Read More
Synairgen's phase II trial begins dosing SNG-001 in home setting to treat COVID-19
Read More
Novartis begins phase II study of DFV-890 for COVID-19 pneumonia
Read More
Glenmark to begin phase III study of favipiravir with umifenovir in moderate COVID-19
Read More
Tavotek and Genmab partner to develop antibody for autoimmune and inflammatory conditions
Read More
Levels of cytokine LIGHT correlate with disease severity and mortality in COVID-19 ARDS study
Read More